摘要肥胖与多种代谢异常相关,包括胰岛素抵抗和2型糖尿病.减轻体重能有效改善胰岛素敏感性,并由此降低肥胖相关的2型糖尿病和心血管疾病风险.研究证实,人胰升糖素样肽1(GLP-1)类似物利拉鲁肽不论单用还是与其他降糖药物联用,都可更好地控制血糖,保护胰岛β细胞功能,并通过抑制摄食和延缓胃肠蠕动减轻体重,这为2型糖尿病患者的治疗提供了新的选择.

abstractsObesity is associated with numerous metabolic abnormalities, including insulin resistance and type 2 diabetes. Losing weight is an effective way of improving insulin sensitivity, thus decreasing the risk of obesityassociated diabetes and chronic cardiovascular disease. There is evidence that Liraglutide, as a human glucagon-like peptide-1 ( GLP-1 ) analogue, either using alone or combining with other glucose-lowering drugs, has effect on improving glycemic control, protecting β-cell function, and reducing body weight via inhibiting feeding behavior and delaying gastrointestinal motility. Therefore, liraglutide is a new option for treating type 2 diabetes patients.